Title
Category
Credits
Event date
Cost
  • Antipsychotics
  • Functional Impairment
  • Movement Disorders
  • Neurology
  • Side Effects
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Learn more from Dr. Joseph McEvoy.
  • Adherence
  • Antipsychotics
  • Cognition
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • Treatment Resistance
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Learn more in this CME activity.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Finally, you can offer patients with tardive dyskinesia approved medications that reduce symptoms. In this CME, Dr Leslie Citrome reviews the evidence.
  • Antipsychotics
  • Bipolar Disorder
  • Depression
  • Diagnostic Tools
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Tardive dyskinesia must be detected early to minimize the risk of permanence. Dr Stephen Saklad provides a refresher in this brief CME activity.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Psychotic Disorders
  • Schizophrenia/ Schizoaffective Disorders
  • Side Effects
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
What are some of the challenges you face in overcoming adherence issues and providing patient-centered care for people living with schizophrenia? Drs Harvey and Kane offer evidence and clinical experience on these topics in this journal CME activity.
  • Adherence
  • Antipsychotics
  • Delivery of Care
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$10.00
The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this journal CME activity that describes expert consensus.
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$10.00
InstructionsClick the red REGISTER button to pay the $10 fee and take the posttest. Click here to return to the JCP CME article.
  • Adherence
  • Antipsychotics
  • Patient/Physician Communication
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Patients may not understand how LAI antipsychotics can benefit them. How can communication be improved? Read this Academic Highlights to find out.
  • Adherence
  • Antipsychotics
  • Schizophrenia/ Schizoaffective Disorders
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this journal CME activity, find experts’ recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
  • Antipsychotics
  • Mood Disorders
  • Movement Disorders
  • Neurology
  • Schizophrenia/ Schizoaffective Disorders
  • Tardive Dyskinesia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Review highlights from two experts’ presentations on identifying and treating tardive dyskinesia. Quotes from actual patients illustrate the embarrassment that they feel and show why even mild movements should be treated if patients are distressed by them.

Pages